Under the Medicare Drug Price Negotiation Program, the HHS secretary negotiates directly with manufacturers on the prices Medicare will pay for pharmaceuticals.

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the amount of Medicare spending subject to price negotiation by billions of dollars annually.

Millions of Medicare Part D enrollees are about to see major relief in their prescription drug costs. 39-year-old makes about $18,000 a month in passive income without a college degree: Here's my best advice

Currently, Medicare has to wait seven years after a traditional drug gets approved by the U.S. Food and Drug Administration (FDA) before it’s eligible for Medicare price negotia

As part of a broader resurgence in pharmaceutical pricing reform and manufacturing policies in 2025, President Donald Trump and

The new guidance builds on previous years’ by increasing the focus on transparency and expanding, per statute, to include details about how Medicare Part B drugs and renegotiation processes will be incorporated into the program.